The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction
Published version of a preprint
Abstract
Abstract Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of this resistance remain elusive. Using a genome-wide loss-of-function screen, we identified that impaired death receptor signaling in ALL led to rapidly progressive disease despite CART19 treatment. This was mediated by an inherent resistance to T-cell cytotoxicity that permitted antigen persistence and was subsequently magnified by the induction of CAR T-cell functional impairment. These findings were validated using samples from two CAR T-cell clinical trials in ALL, where we found that reduced expression of death receptor genes was associated with worse overall survival and reduced T-cell fitness. Our findings suggest that inherent dysregulation of death receptor signaling in ALL directly leads to CAR T-cell failure by impairing T-cell cytotoxicity and promoting progressive CAR T-cell dysfunction. Significance: Resistance to CART19 is a significant barrier to efficacy in the treatment of B-cell malignancies. This work demonstrates that impaired death receptor signaling in tumor cells causes failed CART19 cytotoxicity and drives CART19 dysfunction, identifying a novel mechanism of antigen-independent resistance to CAR therapy. See related commentary by Green and Neelapu, p. 492.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, CRISPR screening showed that loss of tumor-associated death receptors leads to CAR T-cell resistance.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [30]
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096 · cited 1×
“Downstream analysis and visualization was done using HOMER (44) and deepTools2 (45).”
MethodBuenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citation
Cited by
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
Larson, R. C., Kann, M. C., Bailey, S. R., Haradhvala, N. J., Llopis, P. M., Bouffard, A. A., Scarfó, I., Leick, M. B., Grauwet, K., Berger, T. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04585-5 · Cited by 352
Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., et al. (2021) · Blood · doi:10.1182/blood.2020007445 · Cited by 297
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Haradhvala, N. J., Leick, M. B., Maurer, K., Gohil, S. H., Larson, R. C., Yao, N., Gallagher, K. M. E., Katsis, K., Frigault, M. J., Southard, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01959-0 · Cited by 271
Engineered cellular immunotherapies in cancer and beyond
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G., & June, C. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 269
The journey of CAR-T therapy in hematological malignancies
Lu, J., & Jiang, G. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01663-0 · Cited by 217
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Scholler, N., Perbost, R., Locke, F. L., Jain, M. D., Turcan, S., Danan, C., Chang, E. C., Neelapu, S. S., Miklos, D. B., Jacobson, C. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01916-x · Cited by 212
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
Upadhyay, R., Boiarsky, J. A., Pantsulaia, G., Svensson-Arvelund, J., Lin, M. J., Wroblewska, A., Bhalla, S., Scholler, N., Bot, A., Rossi, J. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0756 · Cited by 212
“However, equal efficacy of adoptive cell therapy (23) and checkpoint blockade (24) in perforin-deficient murine models, as well as recent evidence of death receptor signaling gene signatures correlating with CAR-T efficacy (25), supports the notion that other mechanisms may have an underappreciated role in T cell cyto…”
BackgroundDagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 205
“Temporal scRNA-seq data of a few thousand CAR-T cells is highly valuable in monitoring patient progression by identifying predictive biomarkers of clinical response, which can then be used to design personalized therapies [369, 372, 373].”
BackgroundWang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1243 · Cited by 183
Xu, Y., Xiong, J., Sun, X., & Gao, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.001 · Cited by 184
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 175
“Recent data in B-ALL revealed that decreased expression of death receptor signalling molecules, such as components of the FAS pathway, or pro-apoptotic mediators of the extrinsic pathway of apoptosis constitute a novel mechanism of primary resistance to CAR-T cell therapy 162 .”
BackgroundApoptosis in Cancer Biology and Therapy
Moyer, A., Tanaka, K., & Cheng, E. H. (2025) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-115023 · Cited by 173
Bai, Z., Woodhouse, S., Zhao, Z., Arya, R., Govek, K., Kim, D., Lundh, S., Baysoy, A., Sun, H., Deng, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj2820 · Cited by 166
Self-citationShouval, R., Tomas, A. A., Fein, J. A., Flynn, J. R., Markovits, E., Mayer, S., Afuye, A. O., Alperovich, A., Anagnostou, T., Besser, M. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02143 · Cited by 165
“Other transformed low-grade lymphoma 25 (16) 14 (17) 11 (16)”
Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells
Wu, L., Wei, Q., Brzostek, J., & Gascoigne, N. R. J. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0470-3 · Cited by 173
Morgan, M. A., Büning, H., Sauer, M. G., & Schambach, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01965 · Cited by 157
Bailey, S. R., Vatsa, S., Larson, R. C., Bouffard, A. A., Scarfò, I., Kann, M. C., Berger, T. R., Leick, M. B., Wehrli, M., Schmidts, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0181 · Cited by 165
Targeting apoptotic pathways for cancer therapy
Tian, X., Srinivasan, P. R., Tajiknia, V., Uruchurtu, A. S. S., Seyhan, A. A., Carneiro, B. A., Cruz, A. D. L., Pinho-Schwermann, M. P., George, A., Zhao, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179570 · Cited by 170
“Decreased expression of DR4/5 seems to result from defective p53, impaired transport from ribosomes, defective redistribution of DR4/5 in lipid rafts and mutations, epigenetic changes (23, 24, or overexpression of DcR3.”
Engineering-enhanced CAR T cells for improved cancer therapy
Milone, M. C., Xu, J., Chen, S., Collins, M. A., Zhou, J., Powell, D. J., & Melenhorst, J. J. (2021) · Nature Cancer · doi:10.1038/s43018-021-00241-5 · Cited by 156
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Sworder, B. J., Kurtz, D. M., Alig, S., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Esfahani, M. S., Olsen, M. N., Hamilton, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.12.005 · Cited by 158
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia
Leick, M. B., Silva, H. J., Scarfò, I., Larson, R. C., Choi, B. D., Bouffard, A. A., Gallagher, K., Schmidts, A., Bailey, S. R., Kann, M. C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.001 · Cited by 148
Jung, I.-Y., Narayan, V., McDonald, S., Rech, A. J., Bartoszek, R. L., Hong, G., Suhoski, M. M., Xu, J., Boesteanu, A. C., Barber-Rotenberg, J. S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn7336 · Cited by 151
“Given that CAR T-cell dysfunction can be induced by prolonged exposure to cancer cells due to low cytotoxic activity (42), we investigated how the impaired cytotoxicity of PRDM1 KO CAR T-cells affects regulation of exhaustion-associated transcription factors.”
BackgroundAdvancing CAR T cell therapy through the use of multidimensional omics data
Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 135
Born to survive: how cancer cells resist CAR T cell therapy
Lemoine, J., Ruella, M., & Houot, R. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01209-9 · Cited by 143
“Two unbiased genome-wide loss-of-function screens in B-ALL and B cell lymphoma cell lines revealed the crucial role of the death receptor pathway of apoptosis to mediate CAR T cell cytotoxicity [79, 80].”
BackgroundAutophagy protects tumors from T cell–mediated cytotoxicity via inhibition of TNFα-induced apoptosis
Young, T. M., Reyes, C., Pasnikowski, E. M., Castanaro, C., Wong, C. F., Decker, C. E., Chiu, J., Song, H., Wei, Y., Bai, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb9561 · Cited by 118
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Swamydas, M., Murphy, E. V., Ignatz-Hoover, J. J., Malek, E., & Driscoll, J. J. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01234-2 · Cited by 133
“In the related B cell malignancy acute lymphoblastic leukemia (ALL), primary resistance to CD19-directed CAR T cell therapy (CART19) occurs in 10–20% of patients and CART19 resistance is a significant barrier to treatment [184].”
BackgroundJoung, J., Kirchgatterer, P. C., Singh, A., Cho, J. H., Nety, S. P., Larson, R. C., Macrae, R. K., Deasy, R., Tseng, Y., Maus, M. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29205-8 · Cited by 127
Cytokine-mediated CAR T therapy resistance in AML
Bhagwat, A. S., Torres, L., Shestova, O. E., Shestov, M., Mellors, P. W., Fisher, H. R., Farooki, S., Frost, B. F., Loken, M. R., Gaymon, A. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03271-5 · Cited by 122
State of the art in CAR T cell therapy for CD19+ B cell malignancies
Frigault, M. J., & Maus, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129208 · Cited by 113
“The factors underlying disease resistance likely fall into three categories: poor T cell fitness/expansion, loss of the target antigen, and, most recently, tumor mutations that lead to resistance to CAR T cell–mediated killing (76).”
BackgroundPi, M., Kuang, H., Yue, C., Yang, Q., Wu, A., Li, Y., Assaraf, Y. G., Yang, D., & Wu, S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100822 · Cited by 108
Lee, Y. G., Guruprasad, P., Ghilardi, G., Pajarillo, R., Sauter, C. T., Patel, R. P., Ballard, H. J., Hong, S. J., Chun, I., Yang, N., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1026 · Cited by 105
Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
Korell, F., Berger, T. R., & Maus, M. V. (2022) · Med · doi:10.1016/j.medj.2022.05.001 · Cited by 113
Mechanisms of CAR T cell exhaustion and current counteraction strategies
Zhu, X., Li, Q., & Zhu, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1034257 · Cited by 111
“Impressively, they observed that the inherent dysregulation of death receptor signaling in ALL cells directly contributed to CAR T cell exhaustion and correlated with clinical outcomes (Singh et al., 2020).”
BackgroundCucolo, L., Chen, Q., Qiu, J., Yu, Y., Klapholz, M., Budinich, K. A., Zhang, Z., Shao, Y., Brodsky, I. E., Jordan, M. S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.007 · Cited by 104
The EBMT/EHA CAR-T Cell Handbook
Kröger, N., Gribben, J. G., Chabannon, C., Yakoub‐Agha, I., & Einsele, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0 · Cited by 135
CRISPR screens for functional interrogation of immunity
Shi, H., Doench, J. G., & Chi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00802-4 · Cited by 109
Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity
Tuomela, K., Ambrose, A. R., & Davis, D. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867098 · Cited by 111
Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma
van de Donk, N. W. C. J., Themeli, M., & Usmani, S. Z. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0227 · Cited by 92
“Furthermore, early memory T cells are depleted by cyclophosphamide and cytarabine in patients with ALL and non-Hodgkin lymphoma (68).”
InfluentialLee, Y.-H., Lee, H. J., Kim, H. C., Lee, Y., Nam, S. K., Hupperetz, C., Ma, J. S. Y., Wang, X., Singer, O., Kim, W. S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.004 · Cited by 97
Jiang, C., Hao, D., Jain, P., Li, Y., Cai, Q., Yao, Y., Nie, L., Liu, Y., Jin, J., Wang, W., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01655-0 · Cited by 90
Rejeski, K., Jain, M. D., & Smith, E. L. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.04.007 · Cited by 93
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients
Ishii, K., Pouzolles, M., Chien, C. D., Erwin-Cohen, R. A., Kohler, M. E., Qin, H., Lei, H., Kuhn, S. A., Ombrello, A. K., Dulau‐Florea, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130059 · Cited by 82
“, Fas/Fas-L, TRAIL) may reveal distinct mechanisms by which CAR-activated T cells exert cytotoxicity compared with TCR-activated T cells (46, 47).”
BackgroundCD58 loss in tumor cells confers functional impairment of CAR T cells
Yan, X., Chen, D., Ma, X., Wang, Y., Guo, Y., Wei, J., Tong, C., Zhu, Q., Lu, Y., Yu, Y., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007891 · Cited by 79
“In addition to antigen loss and T-cell dysfunction, tumor-intrinsic resistance mechanisms, such as impaired death receptor signaling and NOXA, have been recently reported.(18,22,40) In the present study, we identified a potential mechanism of tumor-intrinsic resistance to CAR T-cell therapy mediated by the loss of CD5…”
BackgroundUnleashing TNF cytotoxicity to enhance cancer immunotherapy
Freeman, A. J., Kearney, C. J., Silke, J., & Oliaro, J. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.10.003 · Cited by 71
Deconvolution of clinical variance in CAR-T cell pharmacology and response
Kirouac, D. C., Zmurchok, C., Deyati, A., Sicherman, J., Bond, C., & Zandstra, P. W. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01687-x · Cited by 75
“Tumor-intrinsic signaling 43,44 and response to lymphodepletion 30 are two prime examples.”
BackgroundTrogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape
Zhai, Y., Du, Y., Li, G., Yu, M., Hu, H., Pan, C., Wang, D., Shi, Z., Yan, X., Li, X., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01708-w · Cited by 86
“Meanwhile, the comprehensive tumor-intrinsic anti-apoptosis modi fi cation, which contributes to antigen-independent treatment failure, 22,23 has also been reported.”
BackgroundAntigen glycosylation regulates efficacy of CAR T cells targeting CD19
Heard, A. D., Landmann, J. H., Hansen, A. R., Papadopolou, A., Hsu, Y.-S., Selli, M. E., Warrington, J. M., Lattin, J., Chang, J., Ha, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31035-7 · Cited by 71
“Data were analyzed using standard genome-wide library analysis pipelines as well as customized R scripts 13,30,31 .”
InfluentialDufva, O., Gandolfi, S., Huuhtanen, J., Dashevsky, O., Duàn, H., Saeed, K., Klievink, J., Nygren, P. J., Bouhlal, J., Lahtela, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.008 · Cited by 87
Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models
Si, X., Xiao, L., Brown, C. E., & Wang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063154 · Cited by 76
“Inhibiting apoptosis pathways in leukemia cells was shown to disrupt their sensitivity to CAR-mediated cytotoxicity, which subsequently triggered CAR T cell exhaustion due to excessive tumor exposure [173].”
BackgroundCell-Based Drug Delivery Systems with Innate Homing Capability as a Novel Nanocarrier Platform
Choi, A., Javius-Jones, K., Hong, S., & Park, H. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s394389 · Cited by 70
“In addition to inducing tumor cell apoptosis, activated T cells can secrete cytokines, including interleukin (IL)2, IL-6, interferon-gamma, and granulocyte-macrophage colony-stimulating factor, to recruit and activate immune cells, such as macrophages and NK cells; this enhances anti-inflammatory and antitumor effects…”
BackgroundFaude, S., Wei, J. M., Muralidharan, K., Xu, X., Wertheim, G. B. W., Paessler, M. E., Bhoj, V. G., Grupp, S. A., Maude, S. L., Rheingold, S. R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004038 · Cited by 62
“Lack of expansion of CAR T cells in NRs can be attributed to disease parameters or T-cell intrinsic factors.(8,16,27) ALC is a measure of T-cell factors, but can also be affected by disease parameters such as extent of disease or lack of CD19 on blasts.”
BackgroundYan, X., Chen, D., Wang, Y., Guo, Y., Tong, C., Wei, J., Zhang, Y., Wu, Z., & Han, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00915-1 · Cited by 67
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
Nixdorf, D., Sponheimer, M., Berghammer, D., Engert, F., Bader, U., Philipp, N., Pasikhani, M. K., Straub, T., Rohrbacher, L., Wange, L. E., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01905-0 · Cited by 63
“Another cause of CAR T-cell failure is T-cell dysfunction, the reasons for which are multifaceted, ranging from the quality of the T cells at the time of apheresis [8, 9], remodeling by the tumor microenvironment [10–14], chronic antigen exposure [15, 16], also caused by the intrinsic resistance of AML cells due to im…”
BackgroundCostimulatory domains direct distinct fates of CAR-driven T cell dysfunction
Selli, M. E., Landmann, J. H., Terekhova, M., Lattin, J., Heard, A. D., Hsu, Y.-S., Chang, T.-C., Chang, J., Warrington, J. M., Ha, H., et al. (2023) · Blood · doi:10.1182/blood.2023020100 · Cited by 91
Duell, J., Leipold, A. M., Appenzeller, S., Fuhr, V., Rauert‐Wunderlich, H., Vià, M. D., Dietrich, O., Toussaint, C., Imdahl, F., Eisele, F., et al. (2023) · Blood · doi:10.1182/blood.2023021672 · Cited by 81
CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions
Gill, S. I., & Brudno, J. N. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320085 · Cited by 75
Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing
Lemoine, J., Ruella, M., & Houot, R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1559 · Cited by 67
“Recently, Singh and colleagues addressed the question of tumorintrinsic resistance to CAR T cells by performing an unbiased genome-wide loss-of-function screen in B-ALL cell lines under CD19 CAR T-cell pressure (47).”
BackgroundArenas, E. J., Martínez-Sabadell, A., Ruiz, I. R., Alonso, M. R., Escorihuela, M., Luque-García, A., Fajardo, C. A., Gros, A., Klein, C., & Arribas, J. (2021) · Nature Communications · doi:10.1038/s41467-021-21445-4 · Cited by 64
Xu, X., Huang, S., Xiao, X., Sun, Q., Liang, X., Chen, S., Zhao, Z., Huo, Z., Tu, S., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569117 · Cited by 66
“(112) found that death receptor ligands in tumors, such as Fas ligand (FasL) and TNF-related apoptosis inducing ligand (TRAIL), are of critical importance for CAR T-cell cytotoxic killing.”
BackgroundDrug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing
Appelbaum, J., Price, A. E., Oda, K., Zhang, J., Leung, W., Tampella, G., Xia, D., So, P. P., Hilton, S. K., Evandy, C., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci162593 · Cited by 56
“In addition, periods of alternating signaling and quiescence may enhance the efficacy of antitumor T cells by preventing T cell exhaustion (48–50) and allowing effector T cells to transition to memory states (29, 30, 51–54) after periods of prolonged antigen exposure.”
BackgroundCherng, H.-J. J., Sun, R., Sugg, B., Irwin, R., Yang, H., Le, C., Deng, Q., Fayad, L., Fowler, N. H., Parmar, S., et al. (2022) · Blood · doi:10.1182/blood.2022015601 · Cited by 57
Bai, Z., Lundh, S. M., Kim, D., Woodhouse, S., Barrett, D. M., Myers, R. M., Grupp, S. A., Maus, M. V., June, C. H., Cámara, P. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002328 · Cited by 62
Zhang, H., Qin, G., Zhang, C., Yang, H., Liu, J., Hu, H., Wu, P. S., Liu, S., Yang, L., Chen, X., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01972-0 · Cited by 54
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
Huang, S., Wang, X., Wang, Y., Wang, Y., Fang, C., Wang, Y., Chen, S., Chen, R., Lei, T., Zhang, Y., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01783-1 · Cited by 62
“Unbiased genome-wide loss-of-function screens in B-ALL and B lymphoma cell lines have revealed that tumor cells with inherent dysregulation of death receptor signaling could be resistant to CAR T-cell killing [91, 92].”
BackgroundResultLiquid biopsy in pancreatic cancer – Current perspective and future outlook
Zhao, Y., Tang, J., Jiang, K., Liu, S.-Y., Aicher, A., & Heeschen, C. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188868 · Cited by 60
Cost-effective strategies for CAR-T cell therapy manufacturing
Abdo, L., Batista-Silva, L. R., & Bonamino, M. H. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.200980 · Cited by 54
“91 Additionally, programmed death-1 ligand-1 (PD-L1) expressed by the tumor cells or the tumor microenvironment inhibits CAR-T cell cytotoxicity in B cell malignancies and have been associated with poor immunotherapy success.”
CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
Yi, F., Cohen, T., Zimmerman, N., Dündar, F., Zumbo, P., Eltilib, R., Brophy, E. J., Arkin, H., Feucht, J., Gormally, M. V., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01009-x · Cited by 57
“To provide additional evidence that CAR-mediated cancer cell lysis occurs independently of the FAS-L–FAS pathway, we reanalyzed results from two published CRISPR screens 41,42 .”
InfluentialWang, X., Xiao, T., Chen, P., Jiang, P., Li, W., Chang, H., Wei, C., Lai, X., Zhang, H., Pan, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01986-y · Cited by 58
“6,7 According to whether the initiation of CAR signaling needs antigen binding, CAR signaling can be categorized into low-level basal tonic signaling (independent of antigen stimulation), 6,8,9 and antigen-dependent high-level signaling.”
Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches
Gu, T., Zhu, M., Huang, H., & Hu, Y. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200256 · Cited by 46
“…the innovative clustered regularly interspaced short palindromic repeats (CRISPR)-based genome-wide loss-of-function screening, scientists have discovered inherent resist‑ ance to CAR-T cell cytotoxicity by impaired cell death signaling, even with positive antigen expression (Singh et al., 2020).”
BackgroundSynthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy
Singh, N., & Maus, M. V. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.010 · Cited by 47
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness
Bansal, R., & Reshef, R. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100695 · Cited by 44
Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges
Jasinski, S., Reyes, F. A. D. L., Yametti, G. C., Pierro, J., Raetz, E. A., & Carroll, W. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00413-3 · Cited by 46
“Impaired death receptor signaling in the leukemia cells is associated with CAR-T failure through antigen-driven T-cell exhaustion without evidence of typical exhaustion epigenetic hallmarks [144].”
BackgroundLim, S. S., Grupp, S. A., & DiNofia, A. M. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29123 · Cited by 46
Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia
Sugita, M., Yamazaki, T., Alhomoud, M., Martinet, J., Latouche, J., Golden, E. B., Boyer, O., van Besien, K., Formenti, S. C., Galluzzi, L., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05829-6 · Cited by 42
“Corroborating the importance of DR signaling in malignant cells for CAR T cell activity, DR defects in the malignant cell compartment have been associated with CAR T cell dysfunction in both preclinical models of ALL and ALL patient samples [12].”
BackgroundYang, Y., Zhang, M., Zhang, Y., Liu, K., & Lu, C. (2023) · Cancers · doi:10.3390/cancers15051563 · Cited by 41
Cuffel, A., Allain, V., Faivre, L., Blasi, R. D., Morin, F., Vercellino, L., Chevalier, M. F., Desnoyer, A., de Jorna, R., Madelaine, I., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007057 · Cited by 40
“Naïve and central memory enriched T cells generated CAR products that retained replicative potential and were associated with complete and sustained remission in various clinical trials.(7-11) Notably, in patients with LBCL treated with axicabtagene ciloleucel (axi-cel; CD19-CD28 CAR T), a higher proportion of naïve/s…”
BackgroundSubeh, Z. Y. A., Poschel, D. B., Redd, P. S., Klement, J. D., Merting, A. D., Yang, D., Mehta, M., Shi, H., Colson, Y. L., Oberlies, N. H., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c04420 · Cited by 42
Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy
Afolabi, L. O., Afolabi, M. O., Sani, M. M., Okunowo, W. O., Yan, D., Chen, L., Zhang, Y., & Wan, X. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1286 · Cited by 49
“antigen-independent mechanism of resistance to CART19 therapy.(49) In another closely related report, the use of”
BackgroundHuang, Y., Qin, Y., He, Y., Qiu, D., Zheng, Y., Wei, J., Zhang, L., Yang, D., & Li, Y. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101082 · Cited by 42
Ivica, N. A., & Young, C. M. (2021) · Healthcare · doi:10.3390/healthcare9081062 · Cited by 46
Dying to Survive—The p53 Paradox
Lees, A., Sessler, T., & McDade, S. S. (2021) · Cancers · doi:10.3390/cancers13133257 · Cited by 41
Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors
Feucht, J., & Sadelain, M. (2020) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2020.09.001 · Cited by 45
“Progressive functional impairment of 19BBz CAR T cells with concomitant transcriptional and epigenetic reprogramming is further observed upon persistent antigen stimulation by deathreceptor-dysregulated leukaemia cells.(54) While T-cell exhaustion may arise following repeated exposure to antigen,(56) CARs can produce…”
BackgroundResistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
Atilla, P. A., & Atilla, E. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101459 · Cited by 41
Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions
Montironi, C., Muñoz‐Pinedo, C., & Eldering, E. (2021) · Cancers · doi:10.3390/cancers13020284 · Cited by 40
“Those findings were validated ex vivo after CD19 CAR T cell treatment in B-ALL patients [85]: expression of death receptor pathway genes in pre-treatment samples correlated with CAR T cell expansion and persistence, as well as patient overall survival.”
BackgroundWarda, W., Rocha, M. N. D., Trad, R., Haderbache, R., Salma, Y., Bouquet, L., Roussel, X., Nicod, C., Deschamps, M., & Ferrand, C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-00284-3 · Cited by 39
What is the future of immunotherapy in multiple myeloma?
Rasche, L., Hudecek, M., & Einsele, H. (2020) · Blood · doi:10.1182/blood.2019004176 · Cited by 35
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
Mueller, J., Schimmer, R. R., Koch, C., Schneiter, F., Fullin, J., Lysenko, V., Pellegrino, C. E., Klemm, N., Russkamp, N. F., Myburgh, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00024-2 · Cited by 37
“…acquired resistance mechanism observed in B-cell lymphoma and B-lymphoblastic leukemia (Fraietta et al, 2018; Shah and Fry, 2019; Sotillo et al, 2015), cancer cell-intrinsic determinants of the ef fi cacy of CAR T-cell therapies are less well understood, particularly in AML (Singh et al, 2020).”
BackgroundMechanisms of response and resistance to CAR T cell therapies
Berger, T. R., & Maus, M. V. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.010 · Cited by 34
Ma, C., Wang, H., Liu, L., Chen, R., Mukherjee, N., Tong, J., Kazmi, S., Fang, X., Witkowski, M. T., Aifantis, I., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01428-2 · Cited by 39
Hagel, K. R., Arafeh, R., Gang, S., Arnoff, T. E., Larson, R. C., Doench, J. G., Mathewson, N. D., Wucherpfennig, K. W., Maus, M. V., & Hahn, W. C. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2245 · Cited by 36
“Specifically, resistance to CD19-targeted CAR T-cell therapy in acute lymphoblastic leukemia was linked to deficiency in FAS and TRAIL death receptor circuitry that rendered tumor cells less sensitive to CAR T-mediated cytotoxicity despite maintenance of CD19 expression (19, 21).”
Ramos, A., Koch, C. E., Liu-Lupo, Y., Hellinger, R. D., Kyung, T., Abbott, K. L., Fröse, J., Goulet, D. R., Gordon, K. S., Eidell, K. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43790-2 · Cited by 37
“428 High JAK/STAT signaling correlates with CAR-T resistance in humans Finally, to examine whether JAK/STAT signaling in tumor cells might also promote 430 resistance to CAR-T therapy in human B cell malignancies, we examined RNAseq data sets generated using pre-treatment bone marrow biopsy samples from patients with…”
Tang, L., Zhang, H., Zhou, F., Wei, Q., Du, M., Wu, J., Li, C., Luo, W., Zhou, J., Wang, X., et al. (2024) · 癌症:英文版 · doi:10.1002/cac2.12525 · Cited by 34
“…studies demonstrated that impaired apoptotic signaling molecules in leukemia cells attenuated CAR-T cell cytotoxicity and drive CAR-T cell dysfunction, further supporting the idea that the apoptosis pathway plays an important role in the successful killing of tumor cells by CAR-T cells [23].”
BackgroundInfluentialBuechner, J., Caruana, I., Künkele, A., Rives, S., Vettenranta, K. K., Bader, P., Peters, C., Baruchel, A., & Calkoen, F. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2021.784024 · Cited by 35
Four challenges to CAR T cells breaking the glass ceiling
Bailey, S. R., Berger, T. R., Graham, C., Larson, R. C., & Maus, M. V. (2022) · European Journal of Immunology · doi:10.1002/eji.202250039 · Cited by 35
Cheloni, G., Karagkouni, D., Pita-Juárez, Y. H., Torres, D., Kanata, E., Liegel, J. J., Avigan, Z. M., Saldarriaga, I., Chedid, G., Rallis, K. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59904-x · Cited by 39
“CD28-based CAR constructs 2,11 – 15,17,18 , We postulated that the long-term ef fi cacy of CAR T therapy is dependent on the downstream activation of non-CAR T cell populations and the development of an adaptive T cell response necessary to prevent disease recurrence.”
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
Stahl, D. J., Gödel, P., Balke‐Want, H., Gholamipoorfard, R., Segbers, P., Tetenborg, L., Koker, M., Dörr, J., Gregor, L., Bachurski, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.013 · Cited by 44
Metadata
- Authors
- Singh, N., Lee, Y. G., Shestova, O., Ravikumar, P., Hayer, K. E., Hong, S. J., Lu, X. M., Pajarillo, R., Agarwal, S., Kuramitsu, S., Orlando, E. J., Mueller, K. T., Good, C. R., Berger, S. L., Shalem, O., Weitzman, M. D., Frey, N. V., Maude, S. L., Grupp, S. A., June, C. H., Gill, S., & Ruella, M.
- Affiliations
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Novartis (Switzerland) (CH)
- 5Novartis Institutes for Biomedical Research, East Hanover, New Jersey.
- Corresponding author
- Singh, Nathan
- Gill, Saar
- Ruella, Marco
- ORCID
- Singh, Nathan
- Lee, Yong Gu
- Ravikumar, Pranali
- Hayer, Katharina E.
- Hong, Seok Jae
- Lu, Xueqing Maggie
- Pajarillo, Raymone
- Agarwal, Sangya
- Kuramitsu, Shunichiro
- Orlando, Elena J.
- Mueller, Karen Thudium
- Good, Charly R.
- Berger, Shelley L.
- Shalem, Ophir
- Weitzman, Matthew D.
- Frey, Noelle V.
- Maude, Shannon L.
- Grupp, Stephan A.
- June, Carl H.
- Gill, Saar
- Ruella, Marco
- Venue
- Cancer Discovery
- Published
- 2020-04-01
- Volume
- 10
- Issue
- 4
- Pages
- 552-567
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3003403042
- Cited by
- 295
- References
- 49
- Citations by year
- 2026: 28 · 2025: 40 · 2024: 35 · 2023: 55 · 2022: 67 · 2021: 51 · 2020: 18
- FWCI
- 17.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Society of Immunotherapy for Cancer Holbrook Kohrt Immunotherapy Translational Fellowship
- Breakthrough Bike Challenge Buz Cooper Scholarship
- NCI (K08CA194256, 1K99CA212302, R00CA212302, 1P01CA214278, R01CA226983)
- American Society of Hematology Scholar Award
- Mark Foundation ASPIRE award
- University of Pennsylvania-Novartis Alliance
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- acute lymphoblastic leukemia, CAR T-cell therapy, CD19, chimeric antigen receptor, death receptor signaling, T cell cytotoxicity, CAR T-cell dysfunction, loss-of-function screen, B-cell malignancies, T cell fitness
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Signal Transduction, Receptors, Death Domain, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.